Eltrombopag-¹³C₄  (Synonyms: SB-497115-¹³C₄)

Eltrombopag-¹³C₄ (SB-497115-¹³C₄) is ^{13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells[1][2][3][4][5].}

Thrombopoietin Receptor, Staphylococcus aureus, Apoptosis^[1][3][5]

446.44

C₂₁¹³C₄H₂₂N₄O₄

1217230-31-3

Solid

Light yellow to orange

O=[13C](/[13C]1=N/NC(C=CC=C2C3=CC(C(O)=O)=CC=C3)=C2O)N(C(C=C4)=CC(C)=C4C)N=[13C]1[13CH3]

Room temperature in continental US; may vary elsewhere.

• [1]. Erickson-Miller CL, et al. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. Stem Cells. 2009 Feb;27(2):424-30.  [Content Brief]

  [2]. Erickson-Miller CL, et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol. 2005 Jan;33(1):85-93.  [Content Brief]

  [3]. Lee H, et al. Repurposing Eltrombopag for Multidrug Resistant Staphylococcus aureus Infections. Antibiotics (Basel). 2021 Nov 9;10(11):1372.  [Content Brief]

  [4]. Juan Zhu, et al. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms. Curr Microbiol. 2021 Feb 21.  [Content Brief]

  [5]. Kurokawa T, et al. The Eltrombopag antitumor effect on hepatocellular carcinoma. Int J Oncol. 2015 Nov;47(5):1696-702.  [Content Brief]